26.31
전일 마감가:
$25.27
열려 있는:
$25.78
하루 거래량:
472.89K
Relative Volume:
1.11
시가총액:
$1.21B
수익:
$722.68M
순이익/손실:
$134.71M
주가수익비율:
9.8539
EPS:
2.67
순현금흐름:
$109.94M
1주 성능:
+1.15%
1개월 성능:
+0.96%
6개월 성능:
+1.90%
1년 성능:
-37.71%
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
명칭
Amphastar Pharmaceuticals Inc
전화
909-980-9484
주소
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
AMPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals Inc
|
26.31 | 1.16B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
120.98 | 52.29B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.61 | 45.27B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 42.39B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.13 | 34.18B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
500.30 | 21.27B | 3.08B | 1.24B | 1.07B | 25.61 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-08-12 | 업그레이드 | Needham | Hold → Buy |
| 2025-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | 개시 | Wells Fargo | Equal Weight |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2023-11-17 | 개시 | BofA Securities | Neutral |
| 2023-07-25 | 재개 | Jefferies | Buy |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-07-29 | 개시 | CapitalOne | Overweight |
| 2022-01-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | 개시 | Northland Capital | Outperform |
| 2019-03-13 | 다운그레이드 | Needham | Buy → Hold |
| 2019-03-13 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-03-13 | 재확인 | Needham | Buy |
| 2017-12-01 | 재확인 | Needham | Buy |
| 2017-11-09 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | 재확인 | Needham | Buy |
| 2017-03-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-05-10 | 재확인 | Needham | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2015-06-19 | 재확인 | Needham | Buy |
| 2015-06-03 | 개시 | Raymond James | Strong Buy |
| 2014-07-21 | 개시 | Needham | Buy |
모두보기
Amphastar Pharmaceuticals Inc 주식(AMPH)의 최신 뉴스
Amphastar Pharmaceuticals Director Sells Over 4,000 Shares - TradingView — Track All Markets
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Up 4.8%Still a Buy? - MarketBeat
Amphastar stock rises after FDA approval of teriparatide injection - Investing.com
Amphastar Announces FDA Approval for Teriparatide Injection - Weatherford Democrat
Amphastar (NASDAQ: AMPH) wins FDA OK for teriparatide pen in $585M US market - Stock Titan
What analysts say about Amphastar Pharmaceuticals Inc 29A stockTechnical Pattern Recognition & Access Free Tools and Start Investing - earlytimes.in
Dir Petersen Files To Sell 4,163 Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView — Track All Markets
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays - MarketBeat
Is Amphastar Pharmaceuticals Mispriced After a Tough Year and Promising Cash Flow Outlook in 2025? - Sahm
Barclays Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Equal-Weight Recommendation - Nasdaq
Amphastar Pharmaceuticals Breaks Below 200-Day Moving AverageNotable for AMPH - Nasdaq
Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates Amphastar Pharmaceuticals at Equalweight With $30 Price Target - marketscreener.com
Marshall Wace LLP Sells 183,037 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Falls 5.2% in Past Week as One-year Earnings and Shareholder Returns Continue Downward Trend - 富途牛牛
American Century Companies Inc. Sells 74,832 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Is Amphastar Pharmaceuticals Stock Built to Withstand a Pullback? - Trefis
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Quantbot Technologies LP - MarketBeat
Why (AMPH) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Would You Still Hold Amphastar Pharmaceuticals Stock If It Fell 30%? - Trefis
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead? - Yahoo Finance
How Amphastar Pharmaceuticals Inc. (29A) stock expands through international marketsOptions Play & Free Community Supported Trade Ideas - Newser
Will Amphastar Pharmaceuticals Inc. stock outperform Nasdaq indexJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - Newser
Will Amphastar Pharmaceuticals Inc. (29A) stock recover faster than industry2025 Retail Activity & Daily Profit Focused Stock Screening - Newser
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of "Hold" from Analysts - MarketBeat
Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why - The Globe and Mail
AMPH: Shifting to proprietary and biosimilar drugs, with major launches and global expansion ahead - TradingView — Track All Markets
Will Amphastar Pharmaceuticals Inc. (29A) stock benefit from infrastructure bill2025 Price Targets & Capital Protection Trade Alerts - Newser
Trend Recap: How strong is Amphastar Pharmaceuticals Inc stock revenue growth - BỘ NỘI VỤ
Will Amphastar Pharmaceuticals Inc. (29A) stock deliver stable dividendsWeekly Trade Recap & Precise Buy Zone Identification - Newser
Is Amphastar Pharmaceuticals Inc. stock a good choice for value investorsTrade Analysis Report & Long-Term Safe Return Strategies - Newser
Is Amphastar Pharmaceuticals Inc. (29A) stock at risk of policy regulationQuarterly Performance Summary & High Yield Equity Trading Tips - Newser
Can Amphastar Pharmaceuticals Inc. (29A) stock double in coming years2025 Price Targets & Real-Time Price Movement Reports - Newser
Creative Planning Acquires 22,493 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Geode Capital Management LLC Buys 18,161 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals (AMPH) Jumps 6.5% After Q3 Beat and Conference Reveal—Has the Investment Case Shifted? - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Is Up 6.5% After Earnings Beat and Pipeline Expansion—What's Changed? - Sahm
A Look at Amphastar Pharmaceuticals (AMPH) Valuation Following Strong Quarterly Results and Pipeline Progress - Yahoo Finance
VP Zhou Files To Sell 20,000 Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView
SG Americas Securities LLC Acquires Shares of 24,448 Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Will Amphastar’s (AMPH) Q3 Earnings Beat Amid Margin Pressure Shift Its Competitive Narrative? - Sahm
Does Amphastar’s New Product Approvals Signal a Turning Point for the Stock in 2025? - Sahm
Magnetar Financial LLC Invests $306,000 in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar (AMPH) Q3 2025 Earnings Call Transcript - The Globe and Mail
Richard Prins Sells 4,179 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - MarketBeat
Understanding Momentum Shifts in (AMPH) - news.stocktradersdaily.com
Amphastar pharma director Prins sells $113,253 in shares By Investing.com - Investing.com Canada
[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Amphastar Pharmaceuticals Director Sells Shares - TradingView
Dir Prins Sells 4,179 ($113.3K) Of Amphastar Pharmaceuticals Inc [AMPH] - TradingView
Amphastar Pharmaceuticals Inc (AMPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):